Scientists at Stanford University developed a new CAR-T therapy that can eradicate many types of childhood tumors in a mouse study, which was published in Clinical Cancer Research on January 17, furtherRead More…
CAR-T VS BsAb: A Comparative Analysis Based on Clinical Data from 2018 American Society of Hematology Annual Meeting
The unique advantages of CAR-T therapy in the treatment of hematological tumors have once again become a hot spot for the recent American Society of Hematology (ASH) Annual Meeting, and bispecific antibodiesRead More…
Blocking GM-CSF Protein Is Expected to Improve CAR-T Cell Therapy
In a new study, researchers from the Mayo Clinic in the United States have developed a new strategy that may improve the performance of chimeric antigen receptor T (CAR-T) cell therapy inRead More…
CAR-T cells Armored with Mini PD-1 Antibody Exhibit Stronger Anti-Tumor Efficacy
Recently, scientists from the Memorial Sloan Kettering (MSK) Cancer Center announced that they have established the latest engineered cells with powerful efficiency, which combine chimeric antigen receptor (CAR) -T cells and checkpointRead More…
Fights Cancer More Effectively——Supercharged Natural Killer Cell (CAR-iNKT)
Recently, a study conducted by the research team from the Imperial College London published in the Cancer Cell showed that supercharged natural killer (NK) cells capable of mass production can effectively fightRead More…
James P. Allison and Tasuku Honjo Shared the 2018 Nobel Prize in Physiology or Medicine
James P. Allison of US and Tasuku Honjo of Japan shared the 2018 Nobel Prize in Physiology or Medicine for “therapy for the discovery of negative immunomodulation for cancer treatment”. As manyRead More…
Two CAR-T Products Were Approved by the European Union for the First Time
Cancer immunotherapy that is given to attention long time has recently made tremendous progress. Novartis’s Kymriah and Gilead’s Yescarta, two star CAR-T products, were approved by the European Union (EU) and becameRead More…
Review: The Expansion of Targetable Biomarkers for CAR T Cell Therapy
A recently published report summarizes the biomarker targets in both hematological and solid malignancies for CAR T cell therapy and discusses potential new biomarker target. A biomarker is an integral part ofRead More…
FDA Approved CAR-macrophage Therapy of Ovarian Cancer into Clinical Trials
Recently, MaxCyte announced that the company’s chimeric antigen receptor (CAR) cell therapy for the treatment of solid tumors based on non-viral messenger RNA (mRNA) technology has been approved by the Food andRead More…
Cytokine Release Syndrome Caused by CAR-T Therapy
Chimeric antigen receptor T cell (CAR-T) therapy is a novel cellular immunotherapy method that introduces chimeric antigen receptors and costimulatory molecules targeting specific targets into T cells by gene editing technology. TumorRead More…